These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34758608)

  • 1. Detection of
    Baer C; Meggendorfer M; Haferlach C; Kern W; Haferlach T
    Haematologica; 2022 Feb; 107(2):562-563. PubMed ID: 34758608
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
    Sanchez R; Ayala R; Alonso RA; Martínez MP; Ribera J; García O; Sanchez-Pina J; Mercadal S; Montesinos P; Martino R; Barba P; González-Campos J; Barrios M; Lavilla E; Gil C; Bernal T; Escoda L; Abella E; Amigo ML; Moreno MJ; Bravo P; Guàrdia R; Hernández-Rivas JM; García-Guiñón A; Piernas S; Ribera JM; Martínez-López J
    Ann Hematol; 2017 Jul; 96(7):1069-1075. PubMed ID: 28451802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
    Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
    Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
    DeBoer R; Koval G; Mulkey F; Wetzler M; Devine S; Marcucci G; Stone RM; Larson RA; Bloomfield CD; Geyer S; Mullighan CG; Stock W
    Leuk Lymphoma; 2016 Oct; 57(10):2298-306. PubMed ID: 26892479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
    Short NJ; Kantarjian H; Kanagal-Shamanna R; Sasaki K; Ravandi F; Cortes J; Konopleva M; Issa GC; Kornblau SM; Garcia-Manero G; Garris R; Higgins J; Pratt G; Williams LN; Valentine CC; Rivera VM; Pritchard J; Salk JJ; Radich J; Jabbour E
    Blood Cancer J; 2020 May; 10(5):61. PubMed ID: 32457305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mutations in the BCR-ABL1 gene in a peruvian patient with acute lymphoblastic leukemia resistant to therapy].
    Ortiz CA; Alvarez YP; Dongo-Pflucker KL; Valdivia E; Mendoza Fernández J; Dávila S; Mora-Alférez P
    Rev Fac Cien Med Univ Nac Cordoba; 2017; 74(2):162-166. PubMed ID: 28657534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
    De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
    BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
    Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Ph+BCR-ABL1
    Baccarani M; Iacobucci I; Chiaretti S; Foà' R; Balasubramanian P; Paietta E; Foroni L; Jeromin S; Izzo B; Spinelli O; Varma N; Menif S; Terragna C; Seth T; Bidet A; Coriu D; Lunghi F; Mayer J; Scappini B; Langabeer S; Maier J; Burt E; Candoni A; Albano F; Luppi M; Zupan I; Lion T; Zadro R; di Raimondo F; Poopak B; Rege-Cambrin G; Annunziata M; Ayala A; Salinas-Viedma V; Ines Prado A; Milner B; Galimberti S; Janssen J; Polli V; Comba L; Borsellino B; Annibali O; Crugnola M; Passamonti F
    Leukemia; 2020 Mar; 34(3):929-931. PubMed ID: 31595038
    [No Abstract]   [Full Text] [Related]  

  • 12. BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with
    Takahashi T; Ichikawa S; Ichinohasama R; Harigae H
    Leuk Lymphoma; 2020 May; 61(5):1265-1267. PubMed ID: 31876209
    [No Abstract]   [Full Text] [Related]  

  • 13. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.
    Soverini S; Vitale A; Poerio A; Gnani A; Colarossi S; Iacobucci I; Cimino G; Elia L; Lonetti A; Vignetti M; Paolini S; Meloni G; di Maio V; Papayannidis C; Amabile M; Guarini A; Baccarani M; Martinelli G; Foà R
    Haematologica; 2011 Apr; 96(4):552-7. PubMed ID: 21193419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute lymphoblastic leukemia associated with RCSD1-ABL1 novel fusion gene has a distinct gene expression profile from BCR-ABL1 fusion.
    De Braekeleer E; Douet-Guilbert N; Guardiola P; Rowe D; Mustjoki S; Zamecnikova A; Al Bahar S; Jaramillo G; Berthou C; Bown N; Porkka K; Ochoa C; De Braekeleer M
    Leukemia; 2013 Jun; 27(6):1422-4. PubMed ID: 23168614
    [No Abstract]   [Full Text] [Related]  

  • 15. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
    Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Jain S; Abraham A
    Arch Pathol Lab Med; 2020 Feb; 144(2):150-155. PubMed ID: 31644323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
    Chiaretti S; Messina M; Foà R
    Cancer; 2019 Jan; 125(2):194-204. PubMed ID: 30561755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
    Płotka A; Lewandowski K
    Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR/ABL1-positive acute lymphoblastic leukemia relapsing as BCR/ABL1-negative acute lymphoblastic leukemia.
    Rizzotto L; Saccenti E; Sofritti O; Daghia G; Volta E; Caprini E; Lupini L; Tammiso E; Bardi A; Lista E; Ciccone M; Russo G; Negrini M; Cuneo A; Rigolin GM
    Leuk Lymphoma; 2013 Sep; 54(9):2065-7. PubMed ID: 23323950
    [No Abstract]   [Full Text] [Related]  

  • 20. The e1a3 BCR-ABL1 fusion transcript in philadelphia chromosome-positive acute lymphoblastic leukemia.
    Langabeer SE
    Ann Lab Med; 2015 Sep; 35(5):540-1. PubMed ID: 26206693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.